Publications

5677 Results

Impact of Treatment Experience on Patient Knowledge of Colony Stimulating Factors Among Patients Receiving Cancer Chemotherapy: Evidence from S1415CD, A Large Pragmatic Trial

Authors
G Lyman;A Bansal;S Sullivan;K Arnold;W Barlow;D Hershman;T Lad;S Ramsey
Journal / Conference
Supportive Care in Cancer Sep 28;31(10):598
Year
2023
Research Committee(s)
Cancer Care Delivery
PMID
PMID37770704
PMC
PMC11060514
Study Number(s)
S1415CD

Sociodemographic risk factors and prediction of aromatase inhibitor non-adherence in women with breast cancer enrolled in SWOG S1105

Authors
DL Hershman;A Moseley;K Arnold;J Gralow;A Neugut;S Ramsey;NL Henry;J Unger
Journal / Conference
SABCS (San Antonio Breast Cancer Symposium, December 5-9, San Antonio, TX), Poster Spotlight Discussion, PS04-08
Year
2023
Research Committee(s)
Cancer Care Delivery
Study Number(s)
S1105

Long-term Follow for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Authors
A Advani;A Moseley;K O'Dwyer;B Wood;J Park;M Wieduwilt;D Jeyakumar;G Yaghmour;E Atallah;A Gerds;S O'Brien;J Liesveld;M Othus;M Litzow;R Stone;E Sharon;C Yeung;J Radich;H Erba
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), poster
Year
2023
Research Committee(s)
Leukemia
Study Number(s)
S1318

Minimal residual disease (MRD) status predicts outcomes in patients with follicular lymphoma (FL) treated with chemo-immunotherapy on SWOG S0016 study

Authors
A Danilov;H Li;M Shadman;L Rimsza;A Zebari;S Smith;M LeBlanc;J Friedberg;C Carlson;J Song
Journal / Conference
ASH Annual Meeting (Dec 9-12,2023, San Diego, CA), poster
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S0016

Class III obesity is associated with worse overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203

Authors
MY Zhang;M Othus;K McMillen;H Erba;G Garcia-Manero;J Pagel;M Sorro;M-E Percival
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), poster
Year
2023
Research Committee(s)
Leukemia
Study Number(s)
S1203

SWOG S1931 (PROBE): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer [NCT04510597]

Authors
H Kim;C Tangen;U Vaishampayan;A Tripathi;B Shuch;S Pal;P Barata;A Tan;L Esfeller;P Lara;A Sanchez;SP Lerner;IM Thompson
Journal / Conference
SUO (Society of Urologic Oncology) (Nov 28-Dec 1, Washington, DC), TIPS, poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1931

Progression-Free Survival (PFS) and toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Authors
S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;F Keller;R Drachtman;A Lamble;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;S Parsons;R Little;M Smith;J Song;S Smith;JW Friedberg;K Kelly
Journal / Conference
ASH Annual Meeting (Dec 9-12, 2023, San Diego), oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged =60 years) enrolled on SWOG S1826

Authors
S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;S Castellino;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships

Authors
RS Herbst;CD Blanke;E Sigal
Journal / Conference
Clinical Cancer Research Oct 30. doi: 10.1158/1078-0432.CCR-23-2690. Online ahead of print
Year
2023
Research Committee(s)
Lung
PMID
PMID37903180
PMC
PMC10767300
Study Number(s)
LUNGMAP

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Authors
C Andreadis;O Bobek;E Hsi;T Fenske;S Geyer;P Stiff;B Till;M Horwitz;F Khimani;R Little;S Dinner;J Friedberg;B Kahl;M Perales;S Devine;J Leonard;N Bartlett
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A051301